Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03471364 · ClinicalTrials.gov registry record · Early Phase 1
Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash
A Early Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 58
- Enrollment target
NCT03471364: Completed Early Phase 1 study, sponsored by Mayo Clinic.
NCT03471364 is a Early Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 58 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03471364, a Early Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 58 participants
- Enrollment target
Study Summary
This early phase I trial studies the side effects of ketoconazole and how well it works in treating participants with ongoing EGFR inhibitor-induced rash. Ketoconazole may reduce the symptoms related to EGFR inhibitor therapy and improve EGFR inhibitor-induced rash.
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Laboratory Biomarker Analysis
- OTHER Questionnaire Administration
- OTHER Placebo Administration
- DRUG Ketoconazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2018-09-25 |
| Est. Completion | 2024-09-15 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03471364
The ClinicalTrials.gov registry entry for NCT03471364 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Quality-of-Life Assessment is the first listed.
NCT03471364 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03471364 about?
NCT03471364 is a clinical study titled "Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash". This early phase I trial studies the side effects of ketoconazole and how well it works in treating participants with ongoing EGFR inhibitor-induced rash. Ketoconazole may reduce the symptoms related to EGFR inhibitor therapy and improve EGFR inhibitor-induced rash.
What is the current status of trial NCT03471364?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 58 participants. The study started on 2018-09-25. Estimated completion is 2024-09-15.
What interventions are being tested in trial NCT03471364?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Laboratory Biomarker Analysis (OTHER), Questionnaire Administration (OTHER), Placebo Administration (OTHER), Ketoconazole (DRUG).
Who is sponsoring clinical trial NCT03471364?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.